Reuters - Shire To Buy SARcode Bioscience For $160M Plus Milestone Payouts

Shire is to buy privately owned U.S. biotech firm SARcode Bioscience, paying $160 million upfront to win rights to a new drug in late-stage development for dry eye diseases.

DealsNorth AmericaUSBriefs